ESR1 and breast cancer: Fulvestrant was effective in both breast cancer subtypes; however, the SERD AZD9496 does not have the same effect in the reduction of ERα stability in invasive lobular breast carcinoma, suggesting that ERα stability and its functional implications are regulated differentially by SERD therapies in both histological subtypes of breast cancer (142).